Gilead Sciences (GILD) Asset Writedowns and Impairment (2016 - 2025)

Gilead Sciences (GILD) has reported Asset Writedowns and Impairment for 5 consecutive years, with $400.0 million the latest figure, recorded in Q4 2025.

• Asset Writedowns and Impairment for Q4 2025 came in at $400.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $590.0 million (down 85.95% YoY), and the FY2025 annual result was $590.0 million, down 85.95% from the prior year.
• Asset Writedowns and Impairment was $400.0 million for Q4 2025 at Gilead Sciences, up from $190.0 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $2.7 billion in Q1 2022 and troughed at $50.0 million in Q4 2023.
• Average Asset Writedowns and Impairment over 4 years is $1.3 billion, with a median of $1.1 billion recorded in 2024.